| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 46 | 2024 | 5319 | 1.760 |
Why?
|
| Lung Neoplasms | 58 | 2024 | 11538 | 1.590 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 9 | 2023 | 259 | 1.160 |
Why?
|
| Retinopathy of Prematurity | 1 | 2022 | 88 | 0.790 |
Why?
|
| Thyroid Neoplasms | 10 | 2023 | 1866 | 0.760 |
Why?
|
| Ophthalmology | 1 | 2022 | 198 | 0.680 |
Why?
|
| Head and Neck Neoplasms | 11 | 2022 | 3976 | 0.560 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 21 | 2021 | 15862 | 0.520 |
Why?
|
| Proton Therapy | 7 | 2024 | 1577 | 0.510 |
Why?
|
| Spinal Cord Compression | 3 | 2005 | 151 | 0.420 |
Why?
|
| Medically Underserved Area | 2 | 2014 | 101 | 0.410 |
Why?
|
| Xerostomia | 3 | 2022 | 190 | 0.400 |
Why?
|
| Hospitals, Public | 1 | 2011 | 64 | 0.390 |
Why?
|
| Polymorphism, Single Nucleotide | 14 | 2014 | 4549 | 0.390 |
Why?
|
| Pleural Neoplasms | 3 | 2019 | 470 | 0.390 |
Why?
|
| Carcinoma, Squamous Cell | 9 | 2021 | 5437 | 0.380 |
Why?
|
| Mesothelioma | 3 | 2019 | 544 | 0.370 |
Why?
|
| Aged | 65 | 2024 | 70117 | 0.370 |
Why?
|
| Tissue Extracts | 1 | 2010 | 48 | 0.370 |
Why?
|
| Thyroidectomy | 5 | 2020 | 486 | 0.360 |
Why?
|
| Middle Aged | 71 | 2021 | 86204 | 0.340 |
Why?
|
| Academic Medical Centers | 2 | 2017 | 672 | 0.340 |
Why?
|
| Gene Transfer Techniques | 1 | 2012 | 716 | 0.340 |
Why?
|
| Chemoradiotherapy | 7 | 2018 | 1946 | 0.330 |
Why?
|
| Radiotherapy, Intensity-Modulated | 6 | 2021 | 2104 | 0.330 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2012 | 1823 | 0.320 |
Why?
|
| Cisplatin | 9 | 2020 | 2432 | 0.310 |
Why?
|
| Polymorphism, Genetic | 6 | 2007 | 1450 | 0.310 |
Why?
|
| Humans | 103 | 2024 | 261506 | 0.300 |
Why?
|
| Nanoparticles | 1 | 2012 | 554 | 0.300 |
Why?
|
| Male | 76 | 2021 | 123000 | 0.300 |
Why?
|
| Female | 78 | 2021 | 141928 | 0.290 |
Why?
|
| Neoplasm Staging | 21 | 2021 | 13658 | 0.280 |
Why?
|
| Neutropenia | 5 | 2017 | 968 | 0.280 |
Why?
|
| Carboplatin | 6 | 2017 | 823 | 0.270 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2006 | 69 | 0.270 |
Why?
|
| Oropharyngeal Neoplasms | 3 | 2022 | 1105 | 0.270 |
Why?
|
| Paclitaxel | 7 | 2017 | 1996 | 0.270 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 598 | 0.260 |
Why?
|
| Antineoplastic Agents | 13 | 2020 | 14289 | 0.260 |
Why?
|
| Molecular Epidemiology | 1 | 2006 | 246 | 0.260 |
Why?
|
| Quinazolines | 4 | 2022 | 923 | 0.250 |
Why?
|
| Genetic Therapy | 1 | 2012 | 1616 | 0.240 |
Why?
|
| Aged, 80 and over | 28 | 2020 | 29902 | 0.240 |
Why?
|
| Abdomen, Acute | 1 | 2024 | 36 | 0.240 |
Why?
|
| Organoplatinum Compounds | 2 | 2011 | 702 | 0.230 |
Why?
|
| Survival Analysis | 13 | 2017 | 9180 | 0.230 |
Why?
|
| Adult | 44 | 2021 | 77950 | 0.230 |
Why?
|
| Exons | 3 | 2022 | 1328 | 0.210 |
Why?
|
| Genetic Variation | 5 | 2014 | 2086 | 0.210 |
Why?
|
| Multivariate Analysis | 8 | 2017 | 4298 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 5 | 2021 | 4975 | 0.200 |
Why?
|
| ROC Curve | 3 | 2022 | 1183 | 0.200 |
Why?
|
| Disease-Free Survival | 13 | 2020 | 10001 | 0.200 |
Why?
|
| Severity of Illness Index | 9 | 2017 | 4320 | 0.200 |
Why?
|
| Arthritis | 1 | 2022 | 139 | 0.200 |
Why?
|
| Malnutrition | 1 | 2024 | 218 | 0.190 |
Why?
|
| Health Status Indicators | 2 | 2013 | 224 | 0.190 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2022 | 275 | 0.190 |
Why?
|
| Carcinoma, Small Cell | 1 | 2003 | 408 | 0.190 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2017 | 2231 | 0.190 |
Why?
|
| Pyruvic Acid | 1 | 2022 | 133 | 0.190 |
Why?
|
| Skin Neoplasms | 3 | 2021 | 4654 | 0.190 |
Why?
|
| Risk Assessment | 9 | 2020 | 6869 | 0.180 |
Why?
|
| Cost of Illness | 3 | 2014 | 498 | 0.180 |
Why?
|
| Patient Care Management | 1 | 2020 | 94 | 0.180 |
Why?
|
| Pemetrexed | 1 | 2019 | 102 | 0.170 |
Why?
|
| Treatment Outcome | 22 | 2022 | 32848 | 0.170 |
Why?
|
| Radiotherapy, Conformal | 2 | 2017 | 902 | 0.170 |
Why?
|
| Proportional Hazards Models | 10 | 2020 | 4988 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2022 | 5539 | 0.170 |
Why?
|
| Radiodermatitis | 1 | 2019 | 75 | 0.170 |
Why?
|
| Inflammation | 3 | 2014 | 2522 | 0.170 |
Why?
|
| Leukopenia | 2 | 2017 | 151 | 0.170 |
Why?
|
| Accidental Falls | 1 | 2020 | 142 | 0.160 |
Why?
|
| Radiation Injuries | 4 | 2017 | 1411 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2017 | 6207 | 0.160 |
Why?
|
| Quality of Life | 6 | 2021 | 4532 | 0.160 |
Why?
|
| Fatigue | 6 | 2019 | 1239 | 0.160 |
Why?
|
| Patient Outcome Assessment | 3 | 2015 | 245 | 0.160 |
Why?
|
| MAP Kinase Signaling System | 1 | 2022 | 848 | 0.150 |
Why?
|
| ras Proteins | 1 | 2022 | 770 | 0.150 |
Why?
|
| Minocycline | 1 | 2019 | 182 | 0.150 |
Why?
|
| Telomere | 2 | 2014 | 505 | 0.150 |
Why?
|
| Radiotherapy Dosage | 5 | 2020 | 3842 | 0.150 |
Why?
|
| Sickness Impact Profile | 3 | 2013 | 139 | 0.140 |
Why?
|
| Mucositis | 1 | 2017 | 148 | 0.140 |
Why?
|
| Ipilimumab | 1 | 2021 | 710 | 0.140 |
Why?
|
| Emergency Treatment | 1 | 2017 | 105 | 0.140 |
Why?
|
| Surveys and Questionnaires | 6 | 2015 | 5687 | 0.140 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 923 | 0.140 |
Why?
|
| Prospective Studies | 9 | 2023 | 12873 | 0.130 |
Why?
|
| Emergencies | 1 | 2017 | 202 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 1493 | 0.130 |
Why?
|
| Ambulatory Care | 2 | 2011 | 554 | 0.130 |
Why?
|
| Dyspnea | 2 | 2016 | 416 | 0.130 |
Why?
|
| DNA, Neoplasm | 4 | 2014 | 1910 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2022 | 5178 | 0.130 |
Why?
|
| Tonsillar Neoplasms | 1 | 2015 | 80 | 0.130 |
Why?
|
| Radiation Pneumonitis | 4 | 2018 | 301 | 0.130 |
Why?
|
| Patient Care Planning | 1 | 2017 | 297 | 0.130 |
Why?
|
| Maximum Tolerated Dose | 2 | 2012 | 1290 | 0.130 |
Why?
|
| Survival Rate | 11 | 2017 | 12221 | 0.130 |
Why?
|
| Reproducibility of Results | 3 | 2022 | 6009 | 0.120 |
Why?
|
| Risk Factors | 13 | 2020 | 17523 | 0.120 |
Why?
|
| Symptom Assessment | 2 | 2015 | 267 | 0.120 |
Why?
|
| HLA-D Antigens | 1 | 2014 | 32 | 0.120 |
Why?
|
| Logistic Models | 5 | 2017 | 3441 | 0.120 |
Why?
|
| Neoplasms | 6 | 2022 | 15193 | 0.120 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2016 | 224 | 0.120 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2014 | 56 | 0.120 |
Why?
|
| Immunotherapy | 3 | 2024 | 3341 | 0.120 |
Why?
|
| Prognosis | 14 | 2021 | 21713 | 0.120 |
Why?
|
| Thrombocytopenia | 2 | 2017 | 846 | 0.120 |
Why?
|
| Diagnostic Imaging | 1 | 2022 | 1162 | 0.120 |
Why?
|
| Cell Cycle | 2 | 2011 | 2084 | 0.120 |
Why?
|
| Double-Blind Method | 4 | 2016 | 2588 | 0.120 |
Why?
|
| Retrospective Studies | 15 | 2024 | 37905 | 0.120 |
Why?
|
| ErbB Receptors | 2 | 2022 | 2295 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2012 | 4938 | 0.110 |
Why?
|
| Proto-Oncogene Proteins B-raf | 4 | 2023 | 1283 | 0.110 |
Why?
|
| Anemia | 2 | 2017 | 689 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2022 | 4757 | 0.110 |
Why?
|
| Pericardium | 1 | 1994 | 157 | 0.110 |
Why?
|
| Stilbenes | 1 | 2013 | 86 | 0.110 |
Why?
|
| Cohort Studies | 8 | 2020 | 9244 | 0.110 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 677 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2021 | 10035 | 0.110 |
Why?
|
| Sulfonamides | 1 | 2022 | 1823 | 0.110 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 461 | 0.110 |
Why?
|
| Propensity Score | 2 | 2016 | 750 | 0.110 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2012 | 67 | 0.110 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2012 | 71 | 0.110 |
Why?
|
| DNA Methylation | 3 | 2008 | 2669 | 0.110 |
Why?
|
| Wnt Proteins | 1 | 2014 | 397 | 0.100 |
Why?
|
| Nomograms | 1 | 2014 | 313 | 0.100 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 1249 | 0.100 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2013 | 292 | 0.100 |
Why?
|
| Wnt Signaling Pathway | 1 | 2014 | 430 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2024 | 3890 | 0.100 |
Why?
|
| Dexamethasone | 1 | 2016 | 1450 | 0.100 |
Why?
|
| Fever | 2 | 2011 | 497 | 0.100 |
Why?
|
| Esophagitis | 4 | 2015 | 202 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 709 | 0.100 |
Why?
|
| Receptors, Chemokine | 1 | 2011 | 114 | 0.100 |
Why?
|
| Sleep Wake Disorders | 4 | 2019 | 348 | 0.100 |
Why?
|
| Etoposide | 3 | 2017 | 870 | 0.100 |
Why?
|
| Radiosurgery | 1 | 2020 | 1330 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2013 | 323 | 0.090 |
Why?
|
| Smoking | 5 | 2013 | 2440 | 0.090 |
Why?
|
| Biomarkers, Tumor | 4 | 2021 | 10331 | 0.090 |
Why?
|
| Texas | 8 | 2014 | 6311 | 0.090 |
Why?
|
| Psychometrics | 2 | 2014 | 937 | 0.090 |
Why?
|
| Combined Modality Therapy | 8 | 2019 | 8865 | 0.090 |
Why?
|
| Plasmids | 1 | 2012 | 837 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2010 | 1248 | 0.090 |
Why?
|
| GTP-Binding Proteins | 1 | 2011 | 321 | 0.090 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 1945 | 0.090 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 482 | 0.090 |
Why?
|
| Cartilage | 1 | 2010 | 128 | 0.090 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 1148 | 0.090 |
Why?
|
| Infant, Newborn | 1 | 2022 | 8223 | 0.080 |
Why?
|
| Time Factors | 6 | 2017 | 12926 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 7702 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2011 | 2316 | 0.080 |
Why?
|
| Carcinoma | 1 | 2020 | 2578 | 0.080 |
Why?
|
| Alphapapillomavirus | 1 | 2010 | 171 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 2 | 2006 | 3101 | 0.080 |
Why?
|
| Receptor, ErbB-2 | 1 | 2018 | 2518 | 0.080 |
Why?
|
| Abnormalities, Multiple | 1 | 1994 | 998 | 0.080 |
Why?
|
| Apoptosis | 2 | 2012 | 7591 | 0.080 |
Why?
|
| Biopsy, Needle | 2 | 2017 | 1363 | 0.080 |
Why?
|
| Genome-Wide Association Study | 2 | 2013 | 2265 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2021 | 3251 | 0.070 |
Why?
|
| Genotype | 6 | 2014 | 4109 | 0.070 |
Why?
|
| Haplotypes | 4 | 2012 | 856 | 0.070 |
Why?
|
| Survivors | 3 | 2021 | 1031 | 0.070 |
Why?
|
| Biological Products | 1 | 2010 | 274 | 0.070 |
Why?
|
| Patient Discharge | 1 | 2011 | 661 | 0.070 |
Why?
|
| Salvage Therapy | 1 | 2015 | 2054 | 0.070 |
Why?
|
| Germ Cells | 1 | 2008 | 335 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 3578 | 0.070 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2022 | 799 | 0.070 |
Why?
|
| Telomere-Binding Proteins | 1 | 2006 | 85 | 0.070 |
Why?
|
| Liposomes | 2 | 2005 | 684 | 0.070 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2008 | 310 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 3639 | 0.070 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2005 | 102 | 0.070 |
Why?
|
| Hospitalization | 2 | 2020 | 2083 | 0.070 |
Why?
|
| Peritoneal Neoplasms | 1 | 2012 | 821 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 1130 | 0.070 |
Why?
|
| Self Report | 3 | 2014 | 756 | 0.070 |
Why?
|
| Sleep Stages | 2 | 2016 | 78 | 0.070 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2005 | 26 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 761 | 0.060 |
Why?
|
| Bayes Theorem | 2 | 2021 | 1021 | 0.060 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2004 | 41 | 0.060 |
Why?
|
| Follow-Up Studies | 6 | 2015 | 14889 | 0.060 |
Why?
|
| Hydroxamic Acids | 1 | 2007 | 442 | 0.060 |
Why?
|
| Neurologic Examination | 1 | 2005 | 245 | 0.060 |
Why?
|
| DNA-Binding Proteins | 2 | 2008 | 4821 | 0.060 |
Why?
|
| Thoracoscopy | 1 | 2005 | 101 | 0.060 |
Why?
|
| Neoplasm Metastasis | 5 | 2015 | 5112 | 0.060 |
Why?
|
| Coronary Artery Disease | 1 | 2013 | 1011 | 0.060 |
Why?
|
| Alternative Splicing | 1 | 2007 | 584 | 0.060 |
Why?
|
| Depression | 1 | 2014 | 1715 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 4892 | 0.060 |
Why?
|
| Sesquiterpenes | 1 | 2004 | 68 | 0.060 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2005 | 169 | 0.060 |
Why?
|
| Cancer Care Facilities | 3 | 2014 | 884 | 0.060 |
Why?
|
| Amifostine | 1 | 2004 | 97 | 0.060 |
Why?
|
| Bleomycin | 1 | 2005 | 467 | 0.060 |
Why?
|
| Alleles | 2 | 2010 | 2437 | 0.060 |
Why?
|
| Drug Carriers | 1 | 2005 | 327 | 0.060 |
Why?
|
| Lymphocytes | 2 | 2007 | 1234 | 0.060 |
Why?
|
| Radiation-Protective Agents | 1 | 2004 | 128 | 0.060 |
Why?
|
| Observer Variation | 1 | 2005 | 671 | 0.060 |
Why?
|
| Observational Studies as Topic | 1 | 2024 | 140 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2022 | 1586 | 0.060 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2007 | 612 | 0.060 |
Why?
|
| Pulmonary Emphysema | 1 | 2005 | 145 | 0.060 |
Why?
|
| Probability | 1 | 2005 | 866 | 0.060 |
Why?
|
| Hypertension | 1 | 2013 | 1503 | 0.060 |
Why?
|
| Mutation | 5 | 2022 | 15179 | 0.060 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 2173 | 0.060 |
Why?
|
| Administration, Oral | 3 | 2015 | 1544 | 0.060 |
Why?
|
| Cell Division | 1 | 2007 | 2489 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 4314 | 0.060 |
Why?
|
| Nutrition Assessment | 1 | 2024 | 169 | 0.060 |
Why?
|
| Heart Defects, Congenital | 1 | 1994 | 1697 | 0.050 |
Why?
|
| Topotecan | 1 | 2003 | 239 | 0.050 |
Why?
|
| Deoxycytidine | 2 | 2012 | 1353 | 0.050 |
Why?
|
| Glycerylphosphorylcholine | 1 | 2022 | 3 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2004 | 476 | 0.050 |
Why?
|
| Succinates | 1 | 2022 | 20 | 0.050 |
Why?
|
| Critical Pathways | 2 | 2017 | 149 | 0.050 |
Why?
|
| Sarcosine | 1 | 2022 | 10 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2021 | 2803 | 0.050 |
Why?
|
| Deglutition Disorders | 2 | 2019 | 447 | 0.050 |
Why?
|
| Ribose | 1 | 2022 | 32 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 6915 | 0.050 |
Why?
|
| Biological Therapy | 1 | 2002 | 58 | 0.050 |
Why?
|
| Lactates | 1 | 2022 | 112 | 0.050 |
Why?
|
| Creatine | 1 | 2022 | 61 | 0.050 |
Why?
|
| Radiotherapy | 3 | 2014 | 1824 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2024 | 337 | 0.050 |
Why?
|
| Adenocarcinoma | 2 | 2014 | 7789 | 0.050 |
Why?
|
| Choline | 1 | 2022 | 76 | 0.050 |
Why?
|
| Nitrogen | 1 | 2022 | 162 | 0.050 |
Why?
|
| Protons | 2 | 2017 | 473 | 0.050 |
Why?
|
| Papillomavirus Infections | 1 | 2010 | 980 | 0.050 |
Why?
|
| Spinal Cord | 1 | 2005 | 690 | 0.050 |
Why?
|
| Case-Control Studies | 5 | 2014 | 6100 | 0.050 |
Why?
|
| Vinblastine | 1 | 2002 | 453 | 0.050 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2015 | 388 | 0.050 |
Why?
|
| Leadership | 1 | 2024 | 254 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 7548 | 0.050 |
Why?
|
| Anorexia | 2 | 2014 | 143 | 0.050 |
Why?
|
| Placebos | 2 | 2012 | 437 | 0.050 |
Why?
|
| Independent Living | 1 | 2020 | 73 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 5159 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 388 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2014 | 11965 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2018 | 1987 | 0.040 |
Why?
|
| Survival | 1 | 2019 | 177 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2022 | 487 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 3472 | 0.040 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2020 | 2370 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 2992 | 0.040 |
Why?
|
| Genes, Neoplasm | 2 | 2013 | 324 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2007 | 2045 | 0.040 |
Why?
|
| Incidence | 2 | 2020 | 5673 | 0.040 |
Why?
|
| United States | 2 | 2017 | 15433 | 0.040 |
Why?
|
| Neoplasms, Second Primary | 1 | 2007 | 1350 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2022 | 862 | 0.040 |
Why?
|
| Oximes | 1 | 2019 | 175 | 0.040 |
Why?
|
| Neck Dissection | 1 | 2019 | 290 | 0.040 |
Why?
|
| Radiography, Interventional | 1 | 2020 | 305 | 0.040 |
Why?
|
| Linkage Disequilibrium | 2 | 2011 | 460 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2020 | 327 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2019 | 314 | 0.040 |
Why?
|
| Mutagenesis, Insertional | 1 | 2018 | 218 | 0.040 |
Why?
|
| Medical Records | 1 | 1998 | 415 | 0.040 |
Why?
|
| Pyridones | 1 | 2019 | 348 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2008 | 8873 | 0.040 |
Why?
|
| Pain | 2 | 2019 | 1658 | 0.040 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2019 | 565 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2011 | 700 | 0.040 |
Why?
|
| Comorbidity | 2 | 2014 | 2352 | 0.030 |
Why?
|
| Stress, Psychological | 2 | 2014 | 1000 | 0.030 |
Why?
|
| Spirometry | 1 | 2016 | 143 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2017 | 477 | 0.030 |
Why?
|
| Glucose | 1 | 2022 | 1248 | 0.030 |
Why?
|
| Lymphopenia | 1 | 2017 | 199 | 0.030 |
Why?
|
| Cell Line, Tumor | 3 | 2022 | 14551 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 280 | 0.030 |
Why?
|
| Cancer Survivors | 1 | 2022 | 650 | 0.030 |
Why?
|
| Platinum | 1 | 2015 | 138 | 0.030 |
Why?
|
| Florida | 1 | 2014 | 113 | 0.030 |
Why?
|
| Pain Measurement | 1 | 1998 | 953 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2007 | 4744 | 0.030 |
Why?
|
| Indoles | 1 | 2020 | 1009 | 0.030 |
Why?
|
| Boston | 1 | 2014 | 108 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 833 | 0.030 |
Why?
|
| Taxoids | 1 | 2017 | 967 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 1998 | 15694 | 0.030 |
Why?
|
| Telomere Homeostasis | 1 | 2014 | 73 | 0.030 |
Why?
|
| Binding Sites | 1 | 2018 | 2171 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 2014 | 176 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2014 | 209 | 0.030 |
Why?
|
| Imidazoles | 1 | 2019 | 999 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2017 | 1391 | 0.030 |
Why?
|
| Spinal Neoplasms | 1 | 1999 | 631 | 0.030 |
Why?
|
| A549 Cells | 1 | 2013 | 124 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 1022 | 0.030 |
Why?
|
| Young Adult | 3 | 2020 | 21445 | 0.030 |
Why?
|
| Stomatitis | 1 | 2014 | 183 | 0.030 |
Why?
|
| Social Class | 1 | 2014 | 310 | 0.030 |
Why?
|
| Everolimus | 1 | 2015 | 415 | 0.030 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2013 | 97 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2020 | 1154 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 973 | 0.030 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2004 | 2341 | 0.030 |
Why?
|
| Pneumonia | 2 | 2011 | 751 | 0.030 |
Why?
|
| Heterografts | 1 | 2014 | 733 | 0.030 |
Why?
|
| Esophageal Neoplasms | 1 | 2005 | 3168 | 0.030 |
Why?
|
| Genes, bcl-2 | 1 | 2012 | 166 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 2139 | 0.030 |
Why?
|
| Caspase 9 | 1 | 2012 | 189 | 0.030 |
Why?
|
| Esophageal Stenosis | 1 | 2011 | 83 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2013 | 374 | 0.020 |
Why?
|
| Health Surveys | 1 | 2013 | 402 | 0.020 |
Why?
|
| Pharyngitis | 1 | 2011 | 41 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 1742 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2014 | 629 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 1656 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2012 | 360 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2016 | 2292 | 0.020 |
Why?
|
| Base Sequence | 2 | 2007 | 4917 | 0.020 |
Why?
|
| Philadelphia Chromosome | 1 | 2014 | 793 | 0.020 |
Why?
|
| Pulmonary Fibrosis | 1 | 2011 | 170 | 0.020 |
Why?
|
| Cell Line | 1 | 2018 | 5114 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2008 | 3203 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2011 | 356 | 0.020 |
Why?
|
| Disease Management | 1 | 2015 | 1052 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 1053 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2017 | 851 | 0.020 |
Why?
|
| Radiography | 1 | 1994 | 1904 | 0.020 |
Why?
|
| Disease Progression | 3 | 2010 | 6682 | 0.020 |
Why?
|
| Constipation | 1 | 2011 | 177 | 0.020 |
Why?
|
| Phenotype | 2 | 2014 | 6295 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2016 | 2218 | 0.020 |
Why?
|
| Echocardiography | 1 | 1994 | 1182 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2012 | 938 | 0.020 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2008 | 83 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 2508 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2012 | 764 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2010 | 521 | 0.020 |
Why?
|
| Capsules | 1 | 2007 | 53 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 1972 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 2291 | 0.020 |
Why?
|
| Age Factors | 1 | 2017 | 5377 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2008 | 6150 | 0.020 |
Why?
|
| Telomeric Repeat Binding Protein 1 | 1 | 2006 | 12 | 0.020 |
Why?
|
| Telomeric Repeat Binding Protein 2 | 1 | 2006 | 25 | 0.020 |
Why?
|
| G2 Phase | 1 | 2007 | 206 | 0.020 |
Why?
|
| rap1 GTP-Binding Proteins | 1 | 2006 | 32 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2014 | 1756 | 0.020 |
Why?
|
| S Phase | 1 | 2007 | 281 | 0.020 |
Why?
|
| Aurora Kinases | 1 | 2006 | 189 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2007 | 242 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 1265 | 0.020 |
Why?
|
| Genome, Human | 1 | 2014 | 1869 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2007 | 726 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 1999 | 7551 | 0.020 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2007 | 430 | 0.020 |
Why?
|
| Cell Movement | 1 | 2013 | 2466 | 0.020 |
Why?
|
| Homozygote | 1 | 2007 | 717 | 0.020 |
Why?
|
| Aurora Kinase A | 1 | 2006 | 202 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 3719 | 0.020 |
Why?
|
| Mice | 2 | 2018 | 34495 | 0.020 |
Why?
|
| Bronchitis | 1 | 2005 | 38 | 0.020 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2005 | 58 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2007 | 575 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2007 | 602 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 7222 | 0.020 |
Why?
|
| DNA Restriction Enzymes | 1 | 2004 | 117 | 0.020 |
Why?
|
| Sulfites | 1 | 2004 | 44 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2010 | 986 | 0.020 |
Why?
|
| Cyclohexanes | 1 | 2004 | 38 | 0.020 |
Why?
|
| Peroxidase | 1 | 2005 | 132 | 0.020 |
Why?
|
| Amines | 1 | 2004 | 85 | 0.020 |
Why?
|
| Cholecystitis | 1 | 2004 | 52 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 3981 | 0.020 |
Why?
|
| Agranulocytosis | 1 | 2004 | 79 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 3552 | 0.020 |
Why?
|
| Mutagens | 1 | 2005 | 187 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2005 | 260 | 0.020 |
Why?
|
| Registries | 1 | 2012 | 2170 | 0.020 |
Why?
|
| Farnesyltranstransferase | 1 | 2004 | 122 | 0.010 |
Why?
|
| DNA Primers | 1 | 2006 | 1399 | 0.010 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2004 | 87 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2012 | 2022 | 0.010 |
Why?
|
| Research Design | 1 | 2011 | 1544 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 1678 | 0.010 |
Why?
|
| Acetylation | 1 | 2004 | 508 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2010 | 1546 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2004 | 445 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2006 | 1064 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2008 | 674 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 2054 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 756 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2004 | 614 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 4971 | 0.010 |
Why?
|
| Gallbladder Neoplasms | 1 | 2004 | 245 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 1323 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2005 | 726 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2004 | 837 | 0.010 |
Why?
|
| Animals | 2 | 2018 | 59536 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2005 | 1944 | 0.010 |
Why?
|
| DNA Repair | 1 | 2008 | 1872 | 0.010 |
Why?
|
| Heart Arrest | 1 | 2004 | 358 | 0.010 |
Why?
|
| Infant | 1 | 2014 | 13310 | 0.010 |
Why?
|
| Piperidines | 1 | 2004 | 1035 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2014 | 16273 | 0.010 |
Why?
|
| Adolescent | 2 | 2014 | 31252 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2005 | 1960 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2002 | 852 | 0.010 |
Why?
|
| Pyridines | 1 | 2004 | 1244 | 0.010 |
Why?
|
| Neurology | 1 | 1999 | 113 | 0.010 |
Why?
|
| Asthma | 1 | 2005 | 871 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2002 | 1299 | 0.010 |
Why?
|
| Forecasting | 1 | 1999 | 694 | 0.010 |
Why?
|
| Patient Care Team | 1 | 1999 | 795 | 0.010 |
Why?
|
| Child | 1 | 2014 | 29154 | 0.010 |
Why?
|
| Radiology | 1 | 1999 | 434 | 0.010 |
Why?
|
| Medical Oncology | 1 | 1999 | 1423 | 0.010 |
Why?
|
| Palliative Care | 1 | 1999 | 2037 | 0.000 |
Why?
|